Instacart downgraded as competition tightening grip on online grocery
BRENTWOOD, Tenn. - Ardent Health (NYSE:ARDT), a healthcare provider with $6.2 billion in annual revenue and a market capitalization of $1.83 billion, has amended and extended its $777.5 million Term Loan Facility, reducing the applicable interest rate by 50 basis points from Term Secured Overnight Financing Rate (SOFR) plus 2.75% to Term SOFR plus 2.25%, the company announced Monday.
The transaction extends the maturity of the facility to September 2032 and is expected to reduce Ardent’s annual interest expense by approximately $3.9 million, according to a company press release.
"This transaction enhances our financial flexibility and strengthens our capital position, allowing Ardent to continue investing in our communities while pursuing strategic growth," said Alfred Lumsdaine, Ardent Health Chief Financial Officer. According to InvestingPro data, the company maintains a healthy current ratio of 2.13, indicating strong liquidity, and has achieved a robust financial health score of 3.25, rated as "GREAT."
Ardent Health operates 30 acute care hospitals and approximately 280 sites of care with over 1,800 employed and affiliated providers across six states. The company focuses on providing healthcare in growing mid-sized urban communities across the United States. Want deeper insights? InvestingPro subscribers get access to exclusive analysis, including Fair Value estimates and 12+ additional ProTips for ARDT.
The company completed its initial public offering and began trading on the New York Stock Exchange earlier this year, and has maintained profitability with earnings per share of $1.83 over the last twelve months.
In other recent news, Ardent Health Partners reported a robust second quarter for 2025, with earnings per share of $0.52, surpassing market expectations. The company achieved a revenue of $1.65 billion, representing an 11.9% increase compared to the previous year. The second-quarter earnings were bolstered by the New Mexico Directed Payment Program approval, which contributed a $65 million EBITDA benefit. Excluding this, Ardent Health’s core revenue growth aligned with management’s expectations, showing mid-single-digit percentage growth year-over-year.
In analyst updates, Truist Securities reiterated its Buy rating for Ardent Health, maintaining a price target of $21, citing strong market positioning and opportunities for growth. UBS also initiated coverage with a Buy rating and set a price target of $17, noting the stock’s decline as an overreaction to Medicaid payment reductions. Meanwhile, JPMorgan adjusted its price target to $15, maintaining a Neutral rating due to the impact of Medicaid tax changes. These developments reflect diverse analyst perspectives on Ardent Health’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.